Browse all 650 ETFs by category, no search needed
Global 184
US market 62
Country 92
Core UCITS 15
Sector 103
Style & factor 112
Theme 45
Dividend 37
Global X Genomics & Biotechnology (GNOM)Overvalued or undervalued?
Look-through valuation · Sector · Expense ratio 0.50 % · ISIN US37954Y4347
Price history (since 2019)
Monthly close since 2019. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Moderna Inc MRNA | 7.5 % | n/a | n/a |
| Twist Bioscience Corp TWST | 6.3 % | n/a | n/a |
| 10X Genomics Inc TXG | 5.5 % | −72.1 % | 66 |
| Guardant Health Inc GH | 5.3 % | n/a | n/a |
| Illumina Inc ILMN | 4.9 % | −55.2 % | 80 |
| Natera Inc NTRA | 4.6 % | −95.1 % | 37 |
| Genscript Biotech Corp 1548 | 3.8 % | −57.2 % | 55 |
| Vertex Pharmaceuticals Inc VRTX | 3.7 % | −49.9 % | 79 |
| Bio-Techne Corp TECH | 3.7 % | −87.1 % | 67 |
| Biomarin Pharmaceutical Inc BMRN | 3.6 % | −40.7 % | 67 |
| Arrowhead Pharmaceuticals Inc ARWR | 3.3 % | −89.2 % | 51 |
| Qiagen NV QGEN | 3.2 % | −11.9 % | 78 |
| Praxis Precision Medicines Inc PRAX | 3.1 % | n/a | n/a |
| Crispr Therapeutics AG CRSP | 3.0 % | −70.7 % | 30 |
| BioNTech SE BNTX | 2.8 % | −56.0 % | 53 |
| Veracyte Inc VCYT | 2.6 % | −59.2 % | 71 |
| Caris Life Sciences, Inc. Common Stock CAI | 2.4 % | −85.6 % | 47 |
| Legend Biotech Corp LEGN | 2.4 % | n/a | n/a |
| Beam Therapeutics Inc BEAM | 2.1 % | n/a | n/a |
| Uniqure NV QURE | 2.1 % | n/a | n/a |
| Eli Lilly and Company LLY | 1.9 % | −66.4 % | 69 |
| Ultragenyx RARE | 1.8 % | −9.8 % | 36 |
| CareDx Inc CDNA | 1.8 % | −80.1 % | 68 |
| GeneDx Holdings Corp. WGS | 1.7 % | −94.5 % | 52 |
| Gilead Sciences Inc GILD | 1.6 % | −2.1 % | 83 |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 49 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +65.2 % below FV
- 2 CHIQ Global X MSCI China Consumer Disc ETF +56.4 % below FV
- 3 FXI iShares China Large-Cap ETF +52.9 % below FV
- 4 KWEB KraneShares CSI China Internet ETF +44.4 % below FV
- 5 FLCH Franklin FTSE China ETF +38.3 % below FV
- 6 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +29.9 % below FV
- 7 MCHI iShares MSCI China ETF +28.1 % below FV
- 8 ITB iShares U.S. Home Construction ETF +18.6 % below FV
- 9 TAN Invesco Solar ETF +17.9 % below FV
- 10 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +8.4 % below FV
Frequently asked about GNOM
Is GNOM overvalued?
What is the fair value of GNOM?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of GNOM?
What is the expense ratio of GNOM?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives Global X Genomics & Biotechnology ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Sep 4, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.